Health Catalyst, Inc.
NASDAQ:HCATMedical - Healthcare Information Services
-$0.04 today
- Market cap
- $98.24M
- Beta
- 1.66
- P/E (TTM)
- -0.5
- EPS (TTM)
- -$3.65
Volume 0.27M
Average 1.24M
HCAT Net Income
Bottom-line profit after all expenses, interest, and taxes.
Health Catalyst, Inc.NASDAQ: HCAT
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income remains negative
Q1 FY2026 net income was -$111.03M, compared with -$23.74M a year earlier. Trailing-twelve-month net income was -$265.26M.
Context
- Net income amounted to 57.2% of revenue in FY2025, up 34.5 pp from a year earlier.
- Net income grew in size in 1 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 4 analysts of -$3.7M (+97.9%) for the fiscal year ending Dec 2026, a step up from the -156.1% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$111.03M-22.0% QoQ
- Last fiscal yearDec 2025
- -$177.97M-156.1% YoY
- LTMMar 2026
- -$265.26M-265.1% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -367.6% | +105.5% | +473.2 pp |
| 1 year | -156.1% | +97.9% | +254.0 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the income statement
- Latest · FY2025
- (177.97M) USD
- Year-over-year change
- -156.1%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (177.97M) | -156.1% |
| FY2024 | 2024-12-31 | (69.5M) | +41.2% |
| FY2023 | 2023-12-31 | (118.15M) | +14.0% |
| FY2022 | 2022-12-31 | (137.4M) | +10.3% |
| FY2021 | 2021-12-31 | (153.21M) | — |
Net Income vs competitors
How HCAT compares with its peers on the latest reported figures
- HCAT's LTM Mar 2026 net income of -$265.26M is the lowest of the 11 companies compared; the peer median is -$76.41M.
- Its year-over-year change of -265.1% is the 10th highest of 11, against a peer median of +19.6%.
- Net income amounts to 87.7% of revenue for HCAT, versus a peer median of 520.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $16.05M | +149.4% | — | 36.2% | |
| LTM Mar 2026 | -$54.64M | +17.6% | — | 167.0% | |
| LTM Mar 2026 | -$61.98M | +35.7% | — | 89.6% | |
| LTM Mar 2026 | -$74.85M | +34.2% | — | 63.7% | |
| LTM Dec 2025 | -$75.02M | -40.2% | — | 576.1% | |
| LTM Mar 2026 | -$77.8M | +39.1% | — | 465.3% | |
| LTM Mar 2026 | -$81.74M | +14.2% | — | 589.8% | |
| LTM Mar 2026 | -$83.01M | +21.5% | — | 36891.1% | |
| LTM Mar 2026 | -$133.22M | +9.9% | — | 1189.1% | |
| LTM Mar 2026 | -$136.85M | -947.5% | — | 1427.1% | |
| LTM Mar 2026 | -$265.26M | -265.1% | — | 87.7% | |
| Peer median (excluding HCAT) | -$76.41M | +19.6% | — | 520.7% | |
Competitors are the stored peer set for HCAT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 241.93M | 276.24M | 295.94M | 306.58M | 311.14M |
| Cost of Revenue | 124.35M | 143.05M | 164.11M | 165.81M | 207M |
| Gross Profit | 117.57M | 133.19M | 131.83M | 140.78M | 104.13M |
| Gross Margin | 48.6% | 48.2% | 44.5% | 45.9% | 33.5% |
| Research & Development | 62.73M | 75.68M | 72.63M | 57.95M | 49.77M |
| Selling, General & Admin | 160.96M | 149.22M | 143.88M | 111.2M | 102.04M |
| Operating Expenses | 261.22M | 273.19M | 258.73M | 210.59M | 140.24M |
| Depreciation & Amortization | 41.11M | 51.53M | 42.22M | 41.43M | 50.5M |
| EBITDA | (101.68M) | (82.92M) | (68.28M) | (10.65M) | (110.35M) |
| EBITDA Margin | -42.0% | -30.0% | -23.1% | -3.5% | -35.5% |
| Operating Income | (143.65M) | (140.01M) | (126.9M) | (69.81M) | (36.1M) |
| Operating Margin | -59.4% | -50.7% | -42.9% | -22.8% | -11.6% |
| Interest Income | 831K | 5.69M | 16.39M | 17.98M | 7.54M |
| Interest Expense | 17.31M | 7.24M | 7.29M | 17.09M | 16.4M |
| Other Income / Expenses | (16.46M) | (1.68M) | 9.11M | 637K | (141.15M) |
| Income Before Tax | (160.11M) | (141.68M) | (117.79M) | (69.17M) | (177.26M) |
| Pre-Tax Margin | -66.2% | -51.3% | -39.8% | -22.6% | -57.0% |
| Income Tax Expense | (6.9M) | (4.28M) | 356K | 333K | 716K |
| Net Income | (153.21M) | (137.4M) | (118.15M) | (69.5M) | (177.97M) |
| Net Margin | -63.3% | -49.7% | -39.9% | -22.7% | -57.2% |
| EPS (Basic) | (3.23) | (2.56) | (2.09) | (1.15) | (2.55) |
| EPS (Diluted) | (3.23) | (2.54) | (2.09) | (1.15) | (2.55) |
| Weighted Avg Shares | 47.49M | 53.72M | 56.42M | 60.19M | 69.9M |
| Weighted Avg Shares (Diluted) | 47.49M | 54.08M | 56.42M | 60.19M | 69.9M |
Health Catalyst, Inc.
NASDAQ:HCAT
Intrinsic Alpha fair value
Locked
Current Price
$1.29
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.